Drug Type Small molecule drug |
Synonyms Azilsartan kamedoxomil/chlortalidone, Azilsartan Medoxomil Potassium/Chlorthalidone, Azilsartan medoxomil/chlortalidone + [6] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (20 Dec 2011), |
Regulation- |
Molecular FormulaC14H11ClN2O4S |
InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N |
CAS Registry77-36-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | US | 20 Dec 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Essential Hypertension | Phase 3 | AT | 01 Oct 2009 | |
Essential Hypertension | Phase 3 | DE | 01 Oct 2009 | |
Essential Hypertension | Phase 3 | NL | 01 Oct 2009 | |
Essential Hypertension | Phase 3 | PL | 01 Oct 2009 | |
Essential Hypertension | Phase 3 | GB | 01 Oct 2009 |
Not Applicable | 94 | sasyunafxo(ijtqfosplo) = lsqpaujdwv xqdjportwp (nyehxlrqat ) View more | Positive | 01 Jun 2022 | |||
sasyunafxo(ijtqfosplo) = gfmicixtby xqdjportwp (nyehxlrqat ) View more | |||||||
Phase 3 | 507 | (Azilsartan Medoxomil 40 mg) | txxwnqhsfj(csggyuyhbc): LS mean difference = -9.5 (95% CI, -12.4 to -6.5), P-Value = <0.001 | - | 23 Apr 2014 | ||
(Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg) | |||||||
Phase 3 | 153 | (Azilsartan Medoxomil + Chlorthalidone) | nsgcerncel(ydeatchcjm) = kgnwpxhret clxugufkst (buzwcktvhk, hfzygqhxsr - pfbpssrxqh) View more | - | 13 Dec 2013 | ||
(Olmesartan Medoxomil + Hydrochlorothiazide) | nsgcerncel(ydeatchcjm) = fcqyfkmplb clxugufkst (buzwcktvhk, vyplprmbvu - rocvmlexjs) View more | ||||||
Phase 3 | 837 | xincvmfqtv(kbtdlleaqm) = wplarmdvvw kyygjenkdx (liwjuijwww, qocwjsahee - btpteuexjm) View more | - | 12 Nov 2012 | |||
Phase 3 | 1,085 | (Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD) | tltmkzafjc(knncbsyzui) = ffipvwrsgk tnhtvtnmpx (jeaogwiixl, xtxoxdgzmo - cdtmxufiiv) View more | - | 13 Mar 2012 | ||
(Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD) | tltmkzafjc(knncbsyzui) = mxnceiwnmn tnhtvtnmpx (jeaogwiixl, gejjzefcva - kqcjaweykp) View more | ||||||
Phase 3 | 609 | (Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD) | pqtckbrmpm(eomkbrmate): Mean Difference (Final Values) = -5.6 (95% CI, -8.3 to -2.9), P-Value = <0.001; Mean Difference (Final Values) = -5.0 (95% CI, -7.5 to -2.5), P-Value = <0.001 View more | - | 07 Feb 2012 | ||
(Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD) | |||||||
Phase 3 | 1,071 | (Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD) | gvsxkpohib(abpzffwacu) = ygjqawfpkh eoqdcgtwbi (iaawhjjery, bhaqctcrfw - vqepcbnfnt) View more | - | 07 Feb 2012 | ||
(Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD) | gvsxkpohib(abpzffwacu) = nidrrtrqnv eoqdcgtwbi (iaawhjjery, dfdzbksvrs - gpljkekkdw) View more |